EntryPoint Capital LLC Invests $429,000 in ClearPoint Neuro, Inc. $CLPT

EntryPoint Capital LLC bought a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,082 shares of the company’s stock, valued at approximately $429,000. EntryPoint Capital LLC owned about 0.13% of ClearPoint Neuro at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of CLPT. Deutsche Bank AG purchased a new position in shares of ClearPoint Neuro during the first quarter worth approximately $63,000. Tower Research Capital LLC TRC purchased a new position in ClearPoint Neuro in the 4th quarter valued at $93,000. Cannon Global Investment Management LLC purchased a new position in ClearPoint Neuro in the 1st quarter valued at $143,000. State of Wyoming purchased a new position in ClearPoint Neuro in the 4th quarter valued at $145,000. Finally, Occudo Quantitative Strategies LP purchased a new position in ClearPoint Neuro in the 4th quarter valued at $155,000. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CLPT has been the topic of a number of analyst reports. Stifel Nicolaus lifted their price objective on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Wall Street Zen lowered shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, July 12th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, ClearPoint Neuro currently has an average rating of “Buy” and an average price target of $19.67.

ClearPoint Neuro Price Performance

ClearPoint Neuro stock opened at $10.37 on Thursday. ClearPoint Neuro, Inc. has a one year low of $9.76 and a one year high of $19.22. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.45 and a current ratio of 7.30. The business has a fifty day moving average of $11.27 and a two-hundred day moving average of $12.93. The company has a market cap of $294.82 million, a P/E ratio of -12.80 and a beta of 0.85.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. The business had revenue of $9.22 million during the quarter, compared to analyst estimates of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. As a group, analysts predict that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ClearPoint Neuro news, Director Timothy T. Richards sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total value of $132,800.00. Following the completion of the sale, the director owned 77,381 shares of the company’s stock, valued at approximately $1,027,619.68. This trade represents a 11.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph Burnett sold 21,247 shares of ClearPoint Neuro stock in a transaction on Monday, June 9th. The stock was sold at an average price of $13.29, for a total value of $282,372.63. Following the transaction, the chief executive officer directly owned 243,522 shares of the company’s stock, valued at $3,236,407.38. This trade represents a 8.02% decrease in their position. The disclosure for this sale can be found here. 6.97% of the stock is currently owned by company insiders.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.